Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.

Pseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (A...

Descripción completa

Detalles Bibliográficos
Autores: Motos A, Yang H, Li Bassi G, Yang M, Meli A, Battaglini D, Cabrera R, Bobi J, Pagliara F, Frigola G, Camprubí-Rimblas M, Fernández-Barat L, Rigol M, Ferrer-Segarra A, Kiarostami K, Martinez D, Nicolau DP, Artigas A, Pelosi P, Vila J, Torres A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1906
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/1906
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148064709&doi=10.1186%2fs13054-023-04331-x&partnerID=40&md5=54d03c6d49031b03a5fd612936935598
Access Level:acceso abierto
Palabra clave:Animal model, Inhaled amikacin, Monolateral pneumonia, Multidrug resistance, Pseudomonas aeruginosa, Severe pneumonia
id ES_2e4cf8ab420d3bbb723dcab697b7a225
oai_identifier_str oai:i3pt.fundanetsuite.com:p1906
network_acronym_str ES
network_name_str España
repository_id_str
spelling Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.Motos AYang HLi Bassi GYang MMeli ABattaglini DCabrera RBobi JPagliara FFrigola GCamprubí-Rimblas MFernández-Barat LRigol MFerrer-Segarra AKiarostami KMartinez DNicolau DPArtigas APelosi PVila JTorres AAnimal model, Inhaled amikacin, Monolateral pneumonia, Multidrug resistance, Pseudomonas aeruginosa, Severe pneumoniaPseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia.BMC2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/1906https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148064709&doi=10.1186%2fs13054-023-04331-x&partnerID=40&md5=54d03c6d49031b03a5fd612936935598CRITICAL CAREISSN: 13648535ISSNe: 1466609Xreponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p19062026-06-21T15:30:37Z
dc.title.none.fl_str_mv Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
title Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
spellingShingle Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Motos A
Animal model, Inhaled amikacin, Monolateral pneumonia, Multidrug resistance, Pseudomonas aeruginosa, Severe pneumonia
title_short Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
title_full Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
title_fullStr Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
title_full_unstemmed Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
title_sort Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
dc.creator.none.fl_str_mv Motos A
Yang H
Li Bassi G
Yang M
Meli A
Battaglini D
Cabrera R
Bobi J
Pagliara F
Frigola G
Camprubí-Rimblas M
Fernández-Barat L
Rigol M
Ferrer-Segarra A
Kiarostami K
Martinez D
Nicolau DP
Artigas A
Pelosi P
Vila J
Torres A
author Motos A
author_facet Motos A
Yang H
Li Bassi G
Yang M
Meli A
Battaglini D
Cabrera R
Bobi J
Pagliara F
Frigola G
Camprubí-Rimblas M
Fernández-Barat L
Rigol M
Ferrer-Segarra A
Kiarostami K
Martinez D
Nicolau DP
Artigas A
Pelosi P
Vila J
Torres A
author_role author
author2 Yang H
Li Bassi G
Yang M
Meli A
Battaglini D
Cabrera R
Bobi J
Pagliara F
Frigola G
Camprubí-Rimblas M
Fernández-Barat L
Rigol M
Ferrer-Segarra A
Kiarostami K
Martinez D
Nicolau DP
Artigas A
Pelosi P
Vila J
Torres A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Animal model, Inhaled amikacin, Monolateral pneumonia, Multidrug resistance, Pseudomonas aeruginosa, Severe pneumonia
topic Animal model, Inhaled amikacin, Monolateral pneumonia, Multidrug resistance, Pseudomonas aeruginosa, Severe pneumonia
description Pseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/1906
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148064709&doi=10.1186%2fs13054-023-04331-x&partnerID=40&md5=54d03c6d49031b03a5fd612936935598
url https://i3pt.portalinvestigacion.com/publicaciones/1906
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148064709&doi=10.1186%2fs13054-023-04331-x&partnerID=40&md5=54d03c6d49031b03a5fd612936935598
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv CRITICAL CARE
ISSN: 13648535
ISSNe: 1466609X
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405394874400768
score 15.811543

Similares en LA Referencia